3-Methyl-2-methylaminobutyraldehyd | 70237-29-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-Methyl-2-methylaminobutyraldehyd
• 英文别名: 3-Methyl-2-(methylamino)butanal
• CAS: 70237-29-5
• 化学式: C₆H₁₃NO
• mdl: MFCD19222656
• 分子量: 115.175
• InChiKey: BWMRKZGGMCOFCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-Methyl-2-methylaminobutyraldehyd 、 [¹⁴C]cyanamide 以55%的产率得到
  参考文献：
  名称：

  SARTORI G.; LANCINI G. C.; CAVALLERI B., J. LABELLED COMPOUNDS AND RADIOPHARM., 1978, 15, 673-680

  摘要：

  DOI：
• 作为产物：
  描述：

  1,1-diethoxy-N,3-dimethylbutan-2-amine 、 盐酸 生成 3-Methyl-2-methylaminobutyraldehyd
  参考文献：
  名称：

  SARTORI G.; LANCINI G. C.; CAVALLERI B., J. LABELLED COMPOUNDS AND RADIOPHARM., 1978, 15, 673-680

  摘要：

  DOI：

文献信息

• Isoform Selective HDAC Inhibitors
  申请人：Kozikowski Alan P.

  公开号：US20100196502A1

  公开（公告）日：2010-08-05

  One aspect of the invention relates to isoform-selective HDAC inhibitors. Also provided are methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy. The invention also provides methods for treating cancer, methods for treating neurological diseases and methods for treating malaria. Additionally, the invention provides pharmaceutical compositions comprising an HDAC inhibitor of the invention; and kits comprising a an HDAC inhibitor of the invention.

  本发明的一个方面涉及选择性同工酶HDAC抑制剂。还提供了一种使癌细胞对放疗的细胞毒性效应敏感的方法。本发明还提供了治疗癌症、神经系统疾病和疟疾的方法。此外，本发明还提供包含本发明的HDAC抑制剂的制药组合物；以及包含本发明的HDAC抑制剂的试剂盒。
• CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS
  申请人：Endocyte, Inc.

  公开号：EP3569251A1

  公开（公告）日：2019-11-20

  Described herein are compositions and methods for use in targeted drug delivery using cell-surface receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in treating disease states caused by pathogenic cell populations.

  本文描述了使用含有亲水间隔连接体的细胞表面受体结合给药共轭物进行靶向给药的组合物和方法，用于治疗由致病细胞群引起的疾病状态。
• SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES
  申请人：Novartis AG

  公开号：EP3960767A2

  公开（公告）日：2022-03-02

  The present application provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination. In one embodiment, the antibodies are modified with cysteines at positions 152 and 375 of the heavy chain constant region, as defined by EU numbering format. In another embodiment, the antibodies are modified with cysteines at position 360 of the heavy chain constant region, and position 107 of the kappa light chain constant region, as defined by EU numbering format.

  本申请通过用半胱氨酸取代亲代抗体或抗体片段恒定区中的至少一个原生氨基酸，提供了修饰抗体或抗体片段的特定位点，这些位点可用作有效载荷或连接子-有效载荷组合的连接位点。在一个实施方案中，抗体在重链恒定区的 152 位和 375 位被半胱氨酸修饰，如欧盟编号格式所定义。在另一个实施方案中，抗体在重链恒定区的 360 位和 kappa 轻链恒定区的 107 位被半胱氨酸修饰，如欧盟编号格式所定义。
• HEMIASTERLIN DERIVATIVES AND USES THEREOF
  申请人：Eisai Co. Ltd.

  公开号：EP1664088A2

  公开（公告）日：2006-06-07
• Spatially-defined macrocyclic compounds useful for drug discovery
  申请人：Ocera Therapeutics, Inc.

  公开号：EP2316846B1

  公开（公告）日：2019-10-02